Video

Sonal Bhatia from Pfizer: Eliquis Continues to Show Positive Results in Real World Trials

Author(s):

It has been several years since Eliquis was approved as an oral anticoagulant but still more research is being done to show its benefits in helping patients with non-valvular atrial fibrillation.

It has been several years since Eliquis was approved as an oral anticoagulant but still more research is being done to show its benefits in helping patients with non-valvular atrial fibrillation.

Sonal Bhatia, MD, from Pfizer discussed the results of this additional research during the American College of Cardiology's annual meeting in Chicago. While Warfarin may still be the preferred treatment method for some patients Bhatia said the results of their studies showed that oral anticoagulants are a viable option for many patients as well.

Related Videos
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Muthiah Vaduganathan, MD, MPH | Credit: Brigham and Women's Hospital
Viet Le, DMSc, PA-C | Credit: APAC
Marianna Fontana, MD, PhD: Declines in Kidney Function Frequent in ATTR-CM  | Image Credit: Radcliffe Cardiology
© 2024 MJH Life Sciences

All rights reserved.